Purolite, an Ecolab company, has opened a new pharmaceutical manufacturing facility in King of Prussia, Pennsylvania.

The 74,000-square-foot plant, which includes an expected 75 new jobs, will produce ion exchange resins for vital healthcare development and pharmaceutical APIs to meet the growing demand for existing and future applications and therapies.

Gergely (GG) Sved, executive vice president and president of Global Healthcare & Life Sciences, was joined by state and local officials at a ribbon-cutting ceremony to open the new facility.

The new plant, the company’s fifth manufacturing facility globally, located at 3700 Horizon Boulevard in King of Prussia, is near Purolite’s headquarters. The facility has two new cleanrooms to manufacture active pharmaceutical ingredients (APIs), which will increase the company’s production of APIs by 67 per cent.

Purolite has more than four decades of experience manufacturing APIs, such as cholestyramine and sodium polystyrene sulfonate and excipients. These applications are vital to time-release formulas and provide the bioavailability necessary for medical treatments to address high cholesterol and heart disease.